IBC's Anti-Angiogenesis Conference to Feature Eight Academic Keynote Presentations
Posted on: Thursday, 13 September 2007, 12:00 CDT
IBC announced today that its upcoming Anti-angiogenesis conference will feature eight academic keynote presentations. Anti-angiogenesis will be held November 12-13, 2007 at the Courtyard Boston Tremont Hotel in Boston, MA.
Keynote presentations include:
-- Anti-angiogenic Therapy in Combination with Radiotherapy: From Bench to Bedside and Back Kevin Camphausen, M.D., National Cancer Institute -- The Role of Circulating Endothelial and Progenitor Cells in Cancer Dan G. Duda, DMD, Ph.D., Massachusetts General Hospital -- The Anti-angiogenesis Activity of Axon Guidance Mediators Michael Klagsbrun, Ph.D., Harvard Medical School/Children's Hospital, Boston -- Drug Delivery Systems for Angiogenesis Inhibitors and Other Biomolecules Robert S. Langer, Sc.D., Massachusetts Institute of Technology -- Mining the Urinary Proteome: Cancer Biomarker Discovery Marsha A. Moses, Ph.D., Harvard Medical School/Children's Hospital, Boston -- Selective Inhibition of Pathologic Angiogenesis in Atherosclerosis Karen S. Moulton, M.D., Harvard Medical School/Children's Hospital, Boston -- Integration of Anti-angiogenic Therapy with Radiation Therapy and other Modalities Michael S. O'Reilly, M.D., The University of Texas M. D. Anderson Cancer Center -- Integrin a4B1 Activation During Bone Marrow Derived Cell Trafficking Promotes Tumor Neovascularization and Growth Michael C. Schmid, Ph.D., University of California San Diego
Michael C. Schmid, Ph.D., University of California San Diego
The Anti-angiogenesis conference is aimed to update attendees on new drugs and to better describe what makes an efficacious anti-angiogenic drug. The conference will also cover how anti-angiogenic drugs fit into the realm of anti-vascular modalities, understand why and what it takes to improve anti-angiogenic drug activity through combination strategies and appropriate drug delivery, and to learn how to follow activity of anti-angiogenic drugs through measurement and validity of biomarkers.
For questions about the Anti-angiogenesis Conference, contact IBC at 800.390.4078 or visit the conference website at http://www.IBCLifeSciences.com/Antiangio.
Writers and editors are encouraged to attend. To request a press pass please contact Sarah Hershberger at shershberger@ibcusa.com.
About IBC Life Sciences
IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life science industry. To develop its programs, IBC actively researches the advancements, technologies and trends impacting and driving the race for new drugs and therapies. For more information, visit www.IBCLifeSciences.com
Contact: Sarah Hershberger IBC Life Sciences Email Contact
SOURCE: IBC Life Sciences
Source: MARKET WIRE
Related Articles
- Alzheimer's Drug Discovery Foundation Hosts 10th International Conference on Alzheimer's Drug Discovery - September 14-15
- Awareness, Inc. Co-Founder and CTO to Present on Business Value of Social Media at Gilbane Boston Conference
- VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
- Molecular to Sponsor Facebook Developer Garage Boston Conference
- FairWinds Partners to Speak at the IQPC Anti-Counterfeiting and Brand Protection Conference in New York
- Callisto's Cancer Drug Atiprimod to Be Presented at Scientific Conference on Cancer Drugs and Angiogenesis
- Medarex to Present at the JPMorgan Small/Mid Cap Boston Conference
- PeptiFarma, Inc. To Present at Medtech Insight's ``Investment In Innovation'' Boston Conference
- PlaCor to Present at Medtech Insight's ``Investment In Innovation'' Boston Conference
- Pharmac Slammed for Restricting Access to Life-Saving Drug
 |
 |
User Comments (0)
RSS Feeds